Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.

Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S.

Ann Intern Med. 2000 May 2;132(9):689-96.

PMID:
10787361
2.

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT..

Maturitas. 2005 Sep 16;52(1):1-10. Review.

PMID:
15963666
3.

Estrogen and progestogen effect on venous thromboembolism in menopausal women.

Archer DF, Oger E.

Climacteric. 2012 Jun;15(3):235-40. doi: 10.3109/13697137.2012.664401. Review.

PMID:
22612609
4.

Menopause and stroke and the effects of hormonal therapy.

Lobo RA.

Climacteric. 2007 Oct;10 Suppl 2:27-31. Review.

PMID:
17882669
5.

The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?

Wells G, Herrington DM.

Drugs Aging. 1999 Dec;15(6):419-22. Review.

PMID:
10641952
6.

A comparative review of the risks and benefits of hormone replacement therapy regimens.

Warren MP.

Am J Obstet Gynecol. 2004 Apr;190(4):1141-67. Review.

PMID:
15118656
7.

Benefits and risks of menopausal estrogen and/or progestin hormone use.

Ernster VL, Bush TL, Huggins GR, Hulka BS, Kelsey JL, Schottenfeld D.

Prev Med. 1988 Mar;17(2):201-23. Review.

8.

Hormone therapy to prevent disease and prolong life in postmenopausal women.

Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR.

Ann Intern Med. 1992 Dec 15;117(12):1016-37. Review.

PMID:
1443971
9.

Postmenopausal hormone therapy. Is it useful for coronary prevention?

Wenger NK.

Cardiol Clin. 1998 Feb;16(1):17-25. Review.

PMID:
9507777
10.

Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations.

Nelson HD, Walker M, Zakher B, Mitchell J.

Ann Intern Med. 2012 Jul 17;157(2):104-13. doi: 10.7326/0003-4819-157-2-201207170-00466. Review.

PMID:
22786830
11.

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy.

Oger E, Scarabin PY.

Drugs Aging. 1999 Jan;14(1):55-61. Review.

PMID:
10069408
12.

[Cardiovascular risk and hormone replacement therapy in menopause].

Plu-Bureau G.

Therapie. 1999 May-Jun;54(3):375-80. Review. French.

PMID:
10500454
14.

Hormone therapy and risk of venous thromboembolism among postmenopausal women.

Canonico M, Scarabin PY.

Climacteric. 2009;12 Suppl 1:76-80. Review.

15.

[Venous and arterial thrombotic events induced by synthetic-steroid hormones or oral contraceptives].

Sugawara H, Kawakami M.

Nihon Rinsho. 1999 Jul;57(7):1657-64. Review. Japanese.

PMID:
10429474
16.

Estrogen dose: the cardiovascular impact.

Panay N.

Climacteric. 2009;12 Suppl 1:91-5. Review.

PMID:
19811250
17.

Postmenopausal hormone replacement therapy and venous thromboembolism.

Wu O.

Gend Med. 2005;2 Suppl A:S18-27. Review.

PMID:
16551553
18.

Evaluating the benefits and risks of postmenopausal hormone therapy.

Cummings SR.

Am J Med. 1991 Nov 25;91(5B):14S-18S. Review.

PMID:
1750410
19.

[Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate].

Ortmann J, Traupe T, Vetter W, Barton M.

Praxis (Bern 1994). 2004 May 19;93(21):904-14. Review. German.

PMID:
15216975
20.

Venous thrombo-embolism and hormone replacement therapy.

Whitehead M, Godfree V.

Baillieres Clin Obstet Gynaecol. 1997 Sep;11(3):587-99. Review.

PMID:
9488793

Supplemental Content

Support Center